Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25320964 | 1.00 | CTSS (0.34) | CTSSCTSK | |
| SCHEMBL9994206 | 0.79 | CTSK (0.38) | CTSSCTSK | |
| SCHEMBL9881546 | 0.79 | CTSK (0.41) | CTSSCTSK | |
| SCHEMBL15821512 | 0.76 | CTSK (0.34) | CTSSCTSK | |
| SCHEMBL31730612 | 0.74 | CTSK (0.60) | CTSK | |
| SCHEMBL26782945 | 0.74 | CTSK (0.60) | CTSK | |
| SCHEMBL10270261 | 0.74 | CTSK (0.60) | CTSK | |
| SCHEMBL25333528 | 0.73 | CTSK (0.40) | CTSSCTSK | |
| SCHEMBL25333530 | 0.73 | CTSK (0.40) | CTSSCTSK | |
| SCHEMBL2824651 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024127350-A1 | 2,6,9-TRISUBSTITUTED PURINES | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-3927698-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-12-29 | — | — | EP | disclosed |
| US-20200352925-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-12 | — | — | US | disclosed |
| WO-2020225230-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-12 | — | — | WO | disclosed |
| US-20200268730-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-27 | — | — | US | disclosed |
| EP-2464368-A1 | CATHEPSIN C INHIBITORS | Glaxo Group Limited (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352925-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | HDGF, FABP1, NR1H4 | CTSS 3084/4885CTSK 2291/4885 |
| US-20200268730-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | HDGF, FABP1, NR1H4 | CTSS 3084/4885CTSK 2291/4885 |
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | CTSE, CTSB, CTSS | CTSS 3/4885CTSK 8/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | CTSS 3101/4885CTSK 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.